Echinocandins in Sepsis

Introduction to Echinocandins

• The European Society of Clinical Microbiology and Infectious Diseases recommends echinocandins as the preferred first-line agents for empirical antifungal therapy in sepsis, especially in hemodynamically unstable patients with septic shock or those with recent azole exposure 1, 2

Risk Assessment for Fungal Infection in Sepsis

• The Intensive Care Medicine society suggests that empiric antifungal therapy should be considered in critically ill septic patients with risk factors for invasive candidiasis when no other cause of fever is identified 2
• Key risk factors for invasive Candida infections include immunocompromised status, such as neutropenia, chemotherapy, transplant, or diabetes mellitus 1
• Prolonged invasive vascular devices, total parenteral nutrition, necrotizing pancreatitis, recent major surgery, prolonged administration of broad-spectrum antibiotics, prolonged hospital/ICU admission, and recent fungal infection are also risk factors 1

First-Line Antifungal Selection

• Echinocandins are the preferred empiric therapy for suspected invasive candidiasis in sepsis, particularly in patients with septic shock or recent azole exposure 1, 2
• The recommended echinocandin dosing regimens are anidulafungin 200 mg loading dose, then 100 mg daily, micafungin 100 mg daily, and caspofungin 70 mg loading dose, then 50 mg daily 2

Alternative Antifungal Options

• Fluconazole is an acceptable alternative in hemodynamically stable, less ill patients without previous triazole exposure or azole-resistant species colonization 1
• Liposomal formulations of amphotericin B are reasonable alternatives in patients with echinocandin intolerance or toxicity 1, 3

Timing and Duration of Therapy

• Antifungal therapy should be initiated as soon as possible in patients with suspected fungal sepsis, ideally within 1 hour of recognition 4, 5
• Empiric antifungal therapy should typically be continued for 14 days in patients who improve clinically 2

Special Considerations

• Central venous catheter removal is strongly recommended in non-neutropenic patients with candidemia 2
• Dilated funduscopic examinations should be performed to rule out endophthalmitis in patients with candidemia 2

Common Pitfalls to Avoid

• Delaying antifungal therapy in high-risk patients with septic shock can significantly increase mortality 2
• Failure to consider local resistance patterns when selecting empiric therapy can lead to inadequate treatment 1